ALKERMES | Beneficio Operativo



Operating Profit Cambio Fecha
AbbVie USD -1490000000 5.32B 2024-12
Acadia Pharmaceuticals USD 153.5M 121.86M 2024-12
ALKERMES USD 162.69M 57.93M 2024-12
Amgen USD 2.31B 182M 2024-12
Biogen USD 441.4M 24.4M 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
Gilead Sciences USD 2.45B 1.56B 2024-12
Intra Cellular Therapies USD -29197000 9.65M 2024-12
Ionis Pharmaceuticals USD -110823000 37.83M 2024-12
J&J USD 3.89B 549M 2024-12
Malin Corporation EUR -700000 1.6M 2024-06
Merck USD 4.3B 369M 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Otsuka Holdings JPY 62.52B 72.25B 2024-12
Pfizer USD -409000000 5.57B 2024-12
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



ALKERMES Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.